Juno Therapeutics (JUNO) announced this morning that it has halted its mid-stage trial study on JCAR015, a leukemia treatment that has resulted in the death of two participants in the study group. At this time there is not enough information available to determine the extent to which this development may undermine Juno’s ability to gain FDA approval for this drug so we are switching to a ‘hold’ until we know more. If more information emerges over the weekend we will address it in this Monday’s issue of Breakthrough Tech Weekly.